Background Scalable, non-invasive tools are critically needed to improve early lung cancer detection and optimize primary care referral pathways. We evaluated Inflammacheck®, a point-of-care device utilizing exhaled breath condensate (EBC) H₂O₂ and physiological parameters with machine learning, for non-invasive lung cancer detection in a real-world screening population.

Methods ExPeL study participants, from the UK Targeted Lung Health Check (TLHC) programme, included individuals with suspected lung cancer and low-risk ever-smoker controls. EBC was collected via Inflammacheck®, measuring H₂O₂, end-tidal CO₂, humidity, temperature, and exhalation flow rate. Multivariate analyses (PCA, LDA, Mahalanobis distance) assessed intrinsic group separation. SMOTE-balanced data trained supervised machine learning models (stacked and voting ensembles), which were then evaluated on held-out test sets. In parallel, untargeted LC–MS metabolomics was performed to identify discriminatory molecular features.

Results Analysing 34 participants with valid EBC data, 83% of cancer cases were early-stage (I–II), reflecting a screening population. Multivariate analysis clearly separated lung cancer and controls across PCA, LDA, and Mahalanobis mapping. The voting ensemble model achieved: Accuracy 85.7%, Sensitivity 80%, Specificity 100%, Precision (PPV) 100%, ROC–AUC 0.90, MCC 0.73. Crucially, no false positives were identified. EBC variables revealed greater dispersion in cancer patients, reflecting physiological heterogeneity missed by univariate analysis. Untargeted metabolomics identified 2,132 features, with four key metabolites yielding an AUC of 0.969 for cancer discrimination.

Discussion Inflammacheck® effectively distinguishes early-stage lung cancer via a rapid, non-invasive breath test, findings which are highly relevant for primary care and screening triage, where non-specific symptoms and low prevalence pose challenges.

Conflict of interest: DP, LD, WA, SG, DT, SK report no conflicts of interest. NB has received payments for speaking from Chiesi, Sanofi and Glaxosmithkline (GSK), support for attending meetings from Astrazeneca (AZ), Chiesi and Sanofi and participates on an advisory board for Sanofi, Chiesi and TEVA. AC is Chief Respiratory Officer of University of Portsmouth Hospital NHS Trust Board

This study was funded by a Wellcome Trust TPA award administered by the University of Manchester Innovation lab. This study was supported by Exhalation Technology Ltd through in-kind contributions of test devices and kits.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Harnessing Exhaled Hydrogen Peroxide for Early Lung Cancer Detection (ExPeL) study received ethical approval from the West Midlands NHS Research Ethics Committee (IRAS: 336691; REC: 24/WM/0028; ISRCTN: 81020233). All participants provided written informed consent.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Conflict of interest: DP, LD, WA, SG, DT, SK report no conflicts of interest. NB has received payments for speaking from Chiesi, Sanofi and Glaxosmithkline (GSK), support for attending meetings from Astrazeneca (AZ), Chiesi and Sanofi and participates on an advisory board for Sanofi, Chiesi and TEVA. AC is Chief Respiratory Officer of University of Portsmouth Hospital NHS Trust Board

All data produced in the present study are available upon reasonable request to the authors